

Approved for use through 08/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**


**Complete if Known**

**(Use as many sheets as necessary)**

**Sheet**

of

Application Number	10/563,278
Filing Date	October 6, 2006
First Named Inventor	Jacques Abraini
Art Unit	1616
Examiner Name	Ernst V. Arnold
Attorney Docket Number	Serie 6132

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/E.A./		EP 1 158 992	05-12-2001	Petzelt et al.		
/E.A./		EP 1 200 103	05-02-2002	Franks et al.		
		<del>FR2012545 (US02/0000174)</del>	<del>02-08-2002</del>	<del>Lecourt et al.</del>		
/E.A./		WO 93/06869	04-15-1993	Vanderipe, D.		
/E.A./		WO 02/09731	02-07-2002	LeMaire et al.		

/Ernst Arnold/

12/03/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/563,278
Filing Date	October 6, 2006
First Named Inventor	Jacques Abraini
Art Unit	1616
Examiner Name	Ernst V. Arnold
Attorney Docket Number	Serie 6132

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/E.A./	C1	PARSONS et al. "Glutamate in CNS Disorders as a Target for Drug Development: An Update", DN&P, Vol. 11, No. 9, Nov. 1998.	
	C2	CHENG, et al. "Intravenous Agents and Intraoperative Neuroprotection", Critical Care Clinics, Vol. 13, No. 1, Jan. 1997, Supplied by The British Library.	
	C3	SAGRATELLA, S., "NMDA Antagonists: Antiepileptic-Neuroprotective Drugs with Diversified Neuropharmacological Profiles", Pharmacological Research, Vol. 21, No. 1/2, 1995.	
	C4	HUDSPITH, M., "Glutamate: A Role in Normal Brain Function, Anaesthesia, Analgesia, and CNS Injury", British Journal of Anaesthesia, 1997; 78:731-747.	
	C5	YAMAKURA et al., "Effects of Gaseous Anesthetics Nitrous Oxide and Xenon on Ligand-gated Ion Channels", American Society of Anesthesiologists, Vol. 93, No. 4, Oct. 2000.	
	C6	TONNER, P., "Xenon as a Replacement for Nitrous Oxide", Harcourt Publishers Ltd., 2001.	
	C7	KOTWICA, et al. "Intracranial Pressure Changes Following Middle Cerebral Artery Occlusion in Rats", Research in Experimental Medicine, 1991.	
	C8	PALMER, et al., "Low Affinity Use-Dependent NMDA Receptor Antagonists Show Promise for Clinical Development", Amino Acids, 2000.	
↓	C9	BURNS, et al., "Glutamate-Dopamine Interactions in the Ventral Striatum: Role in Locomotor Activity and Responding with Conditioned Reinforcement" Psychopharmacology, 1994.	
/E.A./	C10	BENES, F., "Emerging Principles of Altered Neural Circuitry in Schizophrenia" Brain Research Reviews, 2000.	

Examiner Signature	/Ernst Arnold/	Date Considered	12/03/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/563,278
Filing Date	October 6, 2006
First Named Inventor	Jacques Abraini
Art Unit	1616
Examiner Name	Ernst V. Arnold
Attorney Docket Number	Serie 6132

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/E.A./	C11	DIRNAGL, et al., "Pathbiology of Ischaemic Stroke: An Integrated View", Elsevier Science Ltd, 1999.	
/E.A./	C12	DRIAN, et al., "Blockade of AMPA/Kainate Receptors Can Either Decrease or Increase the Survival of Cultured Neocortical Cells Depending on the State of Maturation", Neurochemi	
/E.A./	C13	WANG, et al., "Cerebral Ischemia, Locomotor Activity and Spatial Mapping", Brain Research Reviews, 1990.	
/E.A./	C14	BALDWIN, et al., "Histological, Biochemical and Behavioural Evidence for the Neuroprotective Action of Chlormethiazole Following Prolonged Carotid Artery Occlusion" Neurodegeneration, Vol. 1, 1993.	
/E.A./	C15	CHAZOT, P., "CP-101606 Pfizer Inc." University of Sunderland, 2000.	
	C16		
	C17		
	C18		
	C19		
	C20		

Examiner Signature	/Ernst Arnold/	Date Considered	12/03/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.